Drug Overview

Gamboge resin extract TSB 9 W1 is a specialized, plant-derived substance being studied for its powerful anti-cancer properties. It is extracted from the resin of the Garcinia hanburyi tree. In the field of modern oncology, this extract is considered a Targeted Therapy or a “Smart Drug” because it is designed to seek out specific weaknesses in cancer cells to stop them from growing.

While gamboge resin has been used in traditional medicine for centuries, TSB-9-W1 is a highly purified, pharmaceutical-grade version. It is engineered to deliver the active medicinal compounds—primarily one called gambogic acid—directly to tumors while trying to minimize the impact on the rest of the body.

Generic Name: Gamboge resin extract TSB 9 W1
US Brand Names: None (Currently an investigational drug)
Drug Class: Xanthone derivative; Apoptosis inducer
Route of Administration: Intravenous (IV) infusion
FDA Approval Status: Investigational (Not yet FDA approved for general use; currently in clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Smart Drug works, imagine a cancer cell as a factory that refuses to stop production. TSB-9-W1 works by entering that factory and turning off the main power supply.

At the molecular level, TSB-9-W1 works through several complex pathways:

Activating the “Self-Destruct” Button: The extract targets the mitochondria, which are the powerhouses of the cell. It triggers a process called apoptosis (programmed cell death). It does this by increasing “pro-death” proteins (like Bax) and decreasing “pro-survival” proteins (like Bcl-2).
Inhibiting Transferrin Receptors: Cancer cells have a high number of transferrin receptors on their surface because they “crave” iron to grow. TSB-9-W1 binds to these receptors, blocking the cell from getting the nutrients it needs.
Blocking Growth Signals: The extract interferes with the c-Met signaling pathway. This pathway is like a green light that tells cancer cells to multiply and spread. By turning this light red, TSB-9-W1 helps stop the tumor from growing.
Anti-Angiogenesis: It prevents the tumor from building its own blood vessels. Without these “pipes” to bring in food, the tumor cannot expand.

FDA-Approved Clinical Indications

As an investigational drug, TSB-9-W1 does not yet have official FDA-approved uses for the general public. It is currently being tested in clinical trials for the following:

Oncological Uses (Under Investigation)

Advanced Solid Tumors: Including cancers of the lung, liver, and breast that have not responded to standard treatments.
Hepatocellular Carcinoma (Liver Cancer): Specifically for patients who cannot undergo surgery.
B-cell Malignancies: Certain types of blood and lymph node cancers.

Non-Oncological Uses

There are currently no non-oncological uses for this pharmaceutical extract.

Dosage and Administration Protocols

Because TSB-9-W1 is in the clinical trial phase, the exact dose is carefully calculated by doctors based on the patient’s body surface area and the specific trial phase.

Protocol Detail	Standard Investigational Range
Standard Dose	Often studied between 10 mg/m² and 50 mg/m².
Frequency	Typically administered once or twice a week.
Infusion Time	Usually delivered over 30 to 60 minutes via IV.
Cycle Length	Often given in 21-day or 28-day cycles.

Dose Adjustments:

Hepatic Insufficiency: Since the liver processes this extract, patients with liver damage may require lower doses.
Renal Insufficiency: Doctors monitor kidney function closely, though current data suggests the liver is the primary pathway for clearance.

Clinical Efficacy and Research Results

Recent clinical research (2020–2025) has focused on how well TSB-9-W1 works when other treatments have failed.

Tumor Shrinkage: In early-phase trials, numerical data has shown that a percentage of patients with advanced solid tumors achieved “Stable Disease,” meaning their cancer stopped growing for a period of time.
Disease Progression: Studies have observed that TSB-9-W1 can lower the levels of specific tumor markers in the blood, suggesting the drug is actively attacking the cancer cells.
Survival Trends: While large-scale survival rates (like 5-year survival) are still being calculated in ongoing Phase II and III trials, early data suggests that the drug is well-tolerated enough to allow for long-term treatment in some patients.

Safety Profile and Side Effects

TSB-9-W1 is generally designed to be less toxic than “red-devil” chemotherapies, but it still has a specific safety profile that must be managed.

Black Box Warning:

As an investigational drug, there is currently no official Black Box Warning. However, doctors monitor very closely for signs of liver stress.

Common Side Effects (>10%)

Gastrointestinal Issues: Nausea, mild vomiting, or diarrhea.
Fatigue: Feeling unusually tired or weak after the infusion.
Injection Site Reactions: Redness or soreness where the IV was placed.
Loss of Appetite: A temporary decrease in the desire to eat.

Serious Adverse Events

Hepatotoxicity: Significant changes in liver enzyme levels.
Myelosuppression: A drop in blood cell counts (though this is often milder than standard chemo).
Allergic Reactions: Rare but serious reactions during the infusion.

Management Strategies

For Nausea: Patients are often given “pre-meds” (anti-nausea pills) before the infusion starts.
For Liver Health: Frequent blood tests are required to ensure the liver is processing the drug safely.

Research Areas

Gamboge resin extract is a major area of interest in Immunotherapy research. Scientists are investigating if TSB-9-W1 can “prime” the tumor, making it more visible to the body’s natural immune system. There is also research into using this extract alongside Stem Cell markers to see if the drug can kill “cancer stem cells”—the root cells that often cause cancer to come back after treatment. By targeting these root cells, researchers hope to prevent the cancer from ever returning.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Liver Function Tests (LFTs): To ensure the liver is healthy enough for the drug.
Complete Blood Count (CBC): To check baseline energy and immune levels.
EKG: To monitor heart health before starting the cycles.

Precautions During Treatment

Hydration: Drink plenty of water (2–3 liters) on the day of and the day after your infusion.
Sun Protection: This extract may make your skin more sensitive to the sun. Wear sunscreen and hats.

“Do’s and Don’ts” List

Do tell your doctor about any herbal supplements you are taking, as they may interfere with the resin extract.
Do report any yellowing of the skin or eyes (jaundice) immediately.
Don’t skip your scheduled blood draws; they are the only way to catch liver stress early.
Don’t take any new medications without asking your oncology team first.

Legal Disclaimer

Standard Medical Information Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Gamboge resin extract TSB-9-W1 is an investigational drug and is only available through approved clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This information is based on clinical data available as of 2026.